Ulcerative colitis [UC] and Crohn’s disease [CD] are immune-mediated inflammatory bowel diseases [IBDs] with a complex interplay of genetic and environmental factors involved in their pathogenesis.1 Adalimumab is an anti-tumour necrosis factor [anti-TNF] agent that is approved by the US Food and Drug Administration2 and the European Medicines Agency3 for the treatment of moderately to severely active UC and CD. This evidence concerns the gene TNF and inflammatory bowel disease.